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Strengths and limitations of this study
 ► Prehospital Evaluation of Sensitive Troponin is a 
multicentre prospective observational diagnostic 
accuracy study recruiting patients from four ambu-
lance services in the UK, so we anticipate that our 
result truly reflects UK practice.
 ► The future clinical use of Troponin-only Manchester 
Acute Coronary Syndromes in the prehospital setting 
will be limited due to the observational study design 
pending a definitive randomised controlled trial.
 ► The study captures a large amount of data which al-
low the study team to evaluate different emergency 
department strategies used to risk stratify patients 
with chest pain in the prehospital setting.
 ► The study evaluates three different point-of-care 
troponin assays in conjunction with multiple validat-
ed decision aids.
AbStrACt
Introduction Within the UK, chest pain is one of the most 
common reasons for emergency (999) ambulance calls 
and the most common reason for emergency hospital 
admission. Diagnosing acute coronary syndromes (ACS) 
in a patient with chest pain in the prehospital setting by a 
paramedic is challenging. The Troponin-only Manchester 
Acute Coronary Syndromes (T-MACS) decision rule is a 
validated tool used in the emergency department (ED) to 
stratify patients with suspected ACS following a single 
blood test.
We are seeking to evaluate the diagnostic accuracy of the 
T-MACS decision aid algorithm to ‘rule out’ ACS when used 
in the prehospital environment with point-of-care troponin 
assays. If successful, this could allow paramedics to 
immediately rule out ACS for patients in the ‘very low risk’ 
group and avoid the need for transport to the ED, while 
also risk stratifying other patients using a single blood 
sample taken in the prehospital setting.
Methods and analysis We will recruit patients who 
call emergency (999) ambulance services where the 
responding paramedic suspects cardiac chest pain. The 
data required to apply T-MACS will be prospectively 
recorded by paramedics who are responding to each 
patient. Paramedics will be required to draw a venous 
blood sample at the time of arrival to the patient. Blood 
samples will later be tested in batches for cardiac troponin, 
using commercially available troponin assays. The primary 
outcome will be a diagnosis of acute myocardial infarction, 
established at the time of initial hospital admission. The 
secondary outcomes will include any major adverse 
cardiac events within 30 days of enrolment.
Ethics and dissemination The study obtained approval 
from the National Research Ethics Service (reference: 
18/ES/0101) and the Health Research Authority. We will 
publish our findings in a high impact general medical 
journal.
trial registration number Registration number:  
ClinicalTrials. gov, study ID: NCT03561051
IntroduCtIon
Chest pain is one of the most common reason 
for emergency hospital admission. Clinicians 
will suspect a diagnosis of acute coronary 
syndromes (ACS) in approximately half of 
the patients presenting to emergency depart-
ments (EDs) with chest pain, accounting for 
the majority of these admissions. However, less 
than 20% of those admitted to hospital on the 
suspicion of ACS actually have that diagnosis. 
Most of these admissions could be avoided 
with improved diagnostic technology.1–3
In recent years, there has been much work 
performed in the ED setting with the aim of 
rapidly risk-stratifying patients with cardiac 
chest pain with a view to early discharge of 
those who are at low risk. The Troponin-only 
Manchester Acute Coronary Syndromes 
(T-MACS) is a scientifically derived mathemat-
ical model that combines clinical and histor-
ical features with ECG and cardiac biomarker 
results to determine the probability of ACS 
and assign patients to one of four risk groups: 
very low risk (<2% probability), low risk 
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(2%–5% probability), moderate risk (5%–95% proba-
bility) and high risk (probability ≥95%).
T-MACS has been shown to effectively reduce unneces-
sary hospital admissions when used in the ED.4 It identifies 
45% of patients as eligible for safe, immediate discharge 
following a single blood test.4 5 This is demonstrably 
superior to other early rule-out strategies, including 
that recommended by National Institute for Health and 
Care Excellence (NICE) prior to publication of our find-
ings. In addition to ‘ruling out’ a diagnosis of ACS and 
reducing the need for unnecessary investigations and 
hospital admission, T-MACS can also ‘rule in’ the diag-
nosis in approximately 5% of patients with 95% positive 
predictive value, facilitating early specialist treatment.4–7
The original T-MACS model relies on laboratory-based 
troponin testing. In the multicentre Bedside Evalua-
tion of Sensitive Troponin (BEST) study, we have evalu-
ated the accuracy of T-MACS with point-of-care (POC) 
troponin assays that use portable/handheld analysers, 
which could be used in ambulances. Results from the 
BEST study demonstrate that, with a contemporary POC 
test, T-MACS ‘ruled out’ ACS in 42.7% of patients with 
95.5% sensitivity and 98.7% negative predictive value.5
Using portable POC tests, T-MACS could remove the 
requirement for many patients with suspected ACS to be 
assessed in the hospital, enabling even earlier reassur-
ance for patients and cost savings for the National Health 
Service (NHS). Given the high prevalence of chest 
pain, avoiding ED attendances will reduce crowding, 
which leads to more patient safety incidents and higher 
mortality. Similarly, avoiding unnecessary transfer to 
hospital will free up ambulances to answer other emer-
gency calls. However, as blood tests will be taken sooner 
after symptom onset, it is not safe to assume that T-MACS 
will be accurate in the prehospital environment. We must 
formally evaluate its accuracy in that setting.
Aims and objectives
The primary objective of Pre-hospital Evaluation of Sensi-
tive Troponin is to evaluate whether paramedics can use 
troponin testing by a handheld device with a computer-
ised algorithm at the time of arrival to patients with symp-
toms that cause the treating paramedic to suspect the 
diagnosis of ACS. This would avoid unnecessary transfer 
and enable accurate identification of: (1) patients who do 
not have acute myocardial infarction (AMI) and there-
fore do not need to be taken to hospital; and (2) patients 
who do have AMI and therefore need to be given early 
treatment in the prehospital environment for their condi-
tion. Secondary objectives include validating the T-MACS 
decision aid that could be used to enhance the early diag-
nosis of AMI.
MEthodS And AnAlySIS
design and setting
We will undertake a multicentre, prospective diagnostic 
accuracy study involving ambulance services and EDs in 
the UK. We started participants recruitment on February 
2019 and we will complete recruitment within 12 months.
Within each ambulance service, research activity will be 
focused at ambulance stations or hubs with (1) a track 
record for successful delivery of similar research; and (2) 
which feed into hospitals with (a) adequate central labo-
ratory support for sample processing and storage, and 
(b) clinical protocols that adhere to national and inter-
national standards for the investigation of patients with 
suspected ACS.
data collection
Prehospital environment
Paramedics will record basic clinical data using a brief case 
report form at the time of inclusion. The data collected 
will be sufficient to enable calculation of the T-MACS 
decision aid outcome, including the treating paramedic’s 
interpretation of the patient’s 12-lead ECG. However, in 
this observational study, the T-MACS rule outcome will 
not be known to paramedics.
Paramedics will receive bespoke study training before 
signing the signature log. After participating paramedics 
have provided any necessary urgent treatment and 
obtained verbal consent, they will undertake venepunc-
ture prior to transferring the patient. If paramedics are 
inserting an intravenous cannula, blood will be drawn 
at the same time. Less than 5 mL venous blood will be 
drawn and stored in a lithium heparin bottle labelled 
with a unique study identifier. The date and time of 
venepuncture will be logged on the case report form and 
on the blood bottle. All patients will then be transferred 
to hospital in accordance with routine care.
Hospital environment
On arrival at the hospital, all patients will undergo 
reference standard troponin testing in accordance with 
contemporary national and international guidance. 
Acceptable protocols for reference standard troponin 
testing include:
 ► If a contemporary (not high sensitivity) troponin assay 
is used: laboratory-based troponin testing on arrival 
and either 6 hours after arrival, or 10–12 hours after 
the onset of peak symptoms.
 ► If a high sensitivity troponin assay is used: laborato-
ry-based troponin testing on arrival and either 3 hours 
after arrival, or 6 hours after the onset of peak symp-
toms, unless the patient has undergone investigation 
according to a validated rule-out protocol as advo-
cated in national international guidelines.
A high-sensitivity troponin assay is defined as an assay 
that can detect troponin concentrations in at least 50% of 
apparently healthy individuals with a co-efficient of varia-
tion of <10% at the 99th percentile cut-off.
When the patient arrives at the ED, the local study team 
will be informed. A member of the study team will either 
send the lithium heparin sample drawn in the prehospital 
environment up to the central laboratory for processing 
and storage, or the sample will be processed and stored 
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by a member of the study team who has had appropriate 
training. Once the patient has received all initial treat-
ment in accordance with routine care, a member of the 
local research team will then approach them to answer 
any questions they may have about the study and obtain 
written informed consent.
If the research team cannot obtain written informed 
consent at the time of participant admission to the ED, 
the research paramedic will follow this up and obtain 
written informed consent via post, electronically or over 
the phone. The research paramedic will have 4 weeks to 
obtain written informed consent before the participant 
is withdrawn from the study and their samples destroyed. 
The participant will be made aware of this deadline in 
the information that is sent to them before they are 
approached for consent. If the participant is followed up 
via postal consent, a 1-week grace period will be given to 
allow for delays in the postal service. After this, the partic-
ipant will be withdrawn from the study and their study 
data and samples will be destroyed.
One hour (±30 min) after the prehospital blood 
has been taken; a member of the research team will 
draw another sample of venous blood (<5 mL) into the 
provided lithium heparin bottle labelled with the partic-
ipant’s unique study identifier. The date and time the 
blood was drawn will be logged on the case report form 
and on the blood bottle. This venous blood sample will be 
sent up to the central labs for processing and storage or 
will be processed and stored by the local research team.
Follow-up
Patients will be followed up by reviewing clinical records 
relating to their inpatient course, including data from 
serial troponin testing; other laboratory analyses; length 
of stay; all imaging investigations and procedures and 
details of any haemorrhagic complications. We will also 
contact the participant’s primary care practitioner after 60 
days to obtain information about any additional relevant 
events occurring within 30 days of the initial ambulance 
call. In the small percentage of cases where participants 
do not have a primary care practitioner, we will contact 
participants directly after 30 days. If this is not possible 
and the participant is lost to follow up, then this will be 
recorded on the electronic case report form.
resource use
We will collect comprehensive data about secondary 
healthcare resource use at baseline and 30 days, which 
may be used to subsequently develop a cost-effectiveness 
model. Total direct healthcare costs will be identified and 
quantified according to the UK NHS perspective relevant 
to decision-makers within the NHS.8 At baseline, data 
will be collected with regards to the initial ambulance 
call, such as the date and time of the call, the time of 
ambulance dispatch to the patient, the time of arrival 
to the patient and whether a rapid response unit was 
dispatched. Resource-use data collected at 30 days will 
include: time (hours) and length (days) of hospital stay 
(total; on coronary care, high dependence and intensive 
care units); laboratory, radiological and cardiological 
investigations during the initial hospital stay; nature and 
duration of any procedures or cardiac surgery; manage-
ment of haemorrhagic complications; details of admis-
sions and further ED attendances. Data on resource use 
will be collected using structured data collection forms 
from patient medical records and supplemented by infor-
mation obtained from the patient’s primary care practi-
tioner at follow-up.
Sample processing
On arrival at the destination hospital, the labelled whole 
blood sample that was drawn in the prehospital environ-
ment for research will either be sent to the hospital labo-
ratory for processing and storage along with study-specific 
instructions, or this will be carried out by members of the 
local research team. The local laboratory personnel/
research team members will test the whole blood for 
POC troponin using the Roche cobas h 232 TnT and the 
leftover will be centrifuged to separate out the plasma. 
The plasma will then be stored in separate aliquots and 
transferred to the freezer within 8 hours of collection, 
pending subsequent analysis in batches. The relevant 
manufacturers of commercially available assays have veri-
fied sample stability under these conditions.
The laboratory/research team will process a second 
lithium heparin sample, drawn by the research nurse, 
1 hour (±30 min) after the initial prehospital blood draw. 
For this sample, the local laboratory personnel/research 
team will centrifuge the blood sample and the plasma 
will then be divided into separate aliquots. This will then 
be stored in the freezer within 8 hours of collection. As 
above, samples will be stored pending subsequent analysis 
in batches.
Plasma will later be analysed for POC troponin assays, as 
follows: Abbott i-Stat troponin I and LumiraDx troponin 
I by the central study team. Leftover plasma will continue 
to be stored at the central study site to permit evaluation 
of additional, new POC troponin assays when developed.
Participant selection
We will prospectively approach patients who have called 
for an emergency (999) ambulance with symptoms that 
the attending paramedic suspects may have been caused 
by an ACS.
Inclusion criteria
 ► Adult patients (>18 years).
 ► Called 999 for an emergency ambulance because they 
have experienced pain, discomfort or pressure in the:
 – Chest.
 – Epigastrium.
 – Neck.
 – Jaw.
 – Upper limb without an apparent non-cardiac 
source (compatible with the American Heart 
Association case definitions).9
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 ► Attending paramedic suspects these symptoms may be 
caused by ACS.
Exclusion criteria
 ► Patients with unequivocal evidence of ST-elevation 
myocardial infarction who are being immediately 
transferred for primary percutaneous coronary 
intervention.
 ► Patients in whom an alternative diagnosis (other than 
ACS) is suspected, which would necessitate transfer to 
hospital.
 ► Patients who have not experienced symptoms in the 
previous 24 hours.
Patients who are unable to provide written informed 
consent, either because they lack the mental capacity to 
provide written informed consent or because effective 
communication is not possible (eg, non-English speakers 
in the absence of adequate translation services).
Sample size
The specificity of T-MACS is approximately 45%10 and the 
prevalence of the primary outcome in this cohort will be 
approximately 10%. Assuming that we identify an algo-
rithm with 100% sensitivity and negative predictive value, 
the lower bound of the 95% CI would be>90% for sensi-
tivity and>99% for negative predictive value with a sample 
size of 605 participants. Accounting for potential loss to 
follow-up and missing data (~5%–10% based on experi-
ence in previous similar studies), we plan to include a 
total of 700 participants.
Participant withdrawal
If the participant gives verbal consent for the paramedic 
to proceed with the blood sample, but loses capacity 
before the blood is drawn, the participant will be with-
drawn from the study. All data and samples collected 
up to this point will be destroyed as we will be unable 
to obtain written informed consent. In the event that 
written informed consent cannot be obtained from the 
participant for any other reason, the participant will be 
withdrawn from the study. As above, all data and samples 
collected up to this point will be destroyed.
In the event that a patient who has given written 
informed consent loses capacity before the 30-day 
follow-up, the participant will be withdrawn from the 
study. Any identifiable data or tissue collected up to this 
point would be retained and used in the study as written 
consent had been given. The participant would not be 
followed up at 30 days.
If at any time, the study team believes that remaining on 
the study is not in the participant’s best interest, they will 
approach the participant directly to discuss withdrawal 
from the study. However, if their withdrawal is recom-
mended from their primary caregiver or a relative due to 
psychological distress or a similar reason, the study team 
will not seek to contact the participant any further and 
they will be withdrawn from the study. Any identifiable 
data or tissue collected up to this point would be retained 
and used in the study as consent had been given.
outcomes
The primary outcome will be a diagnosis of AMI, established 
at the time of initial hospital admission. To diagnose AMI 
according to internationally accepted standards requires 
serial troponin sampling. This will help to ensure adequate 
reference standards for the diagnosis of AMI. Outcomes 
will be adjudicated by two independent investigators with 
reference to relevant clinical information but blinded to 
the results of research investigations. Discrepancies will be 
resolved by a third independent investigator. AMI will be 
defined according to the Fourth Universal Definition.11 
By virtue of the inclusion criteria, all patients will have 
symptoms and signs consistent with myocardial ischaemia. 
Briefly, therefore, patients will be deemed to have met this 
outcome if they develop a rise and/or fall of troponin to 
above the 99th percentile.
The secondary outcomes will include any major adverse 
cardiac events, which include cardiovascular death, coro-
nary revascularisation and incident AMI within 30 days. 
All causes of death occurring within 30 days and the final 
diagnoses of all patients will also be recorded.
Statistical analysis
Primary analysis
We will determine the output of the T-MACS decision aid 
using the original, predetermined algorithm. This algo-
rithm computes the probability that each patient has a 
diagnosis of ACS and stratifies patients into four groups on 
the basis of that probability, as follows: very low risk (<2% 
probability)—ACS can be considered ruled out. We hope 
our findings will justify avoiding transport to hospital in this 
group; low risk (2%–5% probability): this group requires 
serial troponin sampling, which could be taken in an ambu-
latory care setting; moderate risk (5%–95% probability): 
this group requires serial troponin sampling but may also 
require additional imaging and therefore requires transfer 
to hospital; high risk (≥95% probability): ACS is ‘ruled in’ 
for this group, which could facilitate direct transfer to a 
specialist centre, facilitating early coronary intervention.
We will calculate the diagnostic accuracy of T-MACS 
as a ‘rule-out’ tool by dichotomising the probability at a 
threshold of 2%. We will then calculate sensitivity, speci-
ficity, positive and negative predictive values, positive and 
negative likelihood ratios and their respective 95% CIs. We 
will also report the number and percentage of patients with 
ACS stratified by T-MACS risk group. The proportion of 
transfers to the ED that could have been avoided will be 
calculated.
Secondary analyses
We are planning to conduct several secondary analyses. 
First, we will evaluate the diagnostic accuracy of T-MACS 
as a ‘rule-in’ tool, which would facilitate direct transfer 
to tertiary care heart attack centres and may enable 
patients to benefit from earlier specialist treatment such as 
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percutaneous coronary intervention in future. To do this, 
we will dichotomise T-MACS at the probability threshold of 
95% (ie, analysing classification as ‘high risk’ vs all other 
risk groups). We will again calculate sensitivity, specificity, 
positive and negative predictive values, positive and nega-
tive likelihood ratios and their respective 95% CIs. Finally, 
we will calculate the proportion of patients with and without 
ACS who would have been transported to tertiary care 
facilities if T-MACS had been used in practice, and we will 
compare those findings to the observed practice in routine 
care. As some patients may have final diagnoses other than 
ACS, we will also retrieve the final coded diagnosis for all 
patients and present a descriptive analysis stratified by 
T-MACS risk group.
Second, we will evaluate the diagnostic accuracy of 
other hospital-based strategies used to rule-out, rule-in or 
‘risk-stratify’ patients with AMI or ACS such as the HEART 
(History, ECG, Age, Risk factors, Troponin) score, History 
and ECG only Manchester Acute Coronary Syndromes 
(HE-MACS) decision aid, limit of detection strategy and 
selected cut-offs (eg, the 99th percentile of a reference 
population).
Economic analyses
Total direct healthcare costs (resource use × unit costs data) 
will be calculated using a microcosting study run by our 
team (ISRCTN 86818215) and will compare the novel diag-
nostic pathway versus estimates for current care.12 Where 
appropriate, we will proceed to formal cost-effectiveness 
analysis using a de novo decision-analytic model populated 
with data collected during this study and other externally 
published data. The model would extrapolate the effects of 
implementing the novel diagnostic pathway derived in this 
work on healthcare resource use and health status (quality 
adjusted life years as informed by the EQ-5D) versus current 
diagnostic and treatment pathways. Economic analyses will 
be led by AT.
Patient and public involvement
To maximise the potential for clinical impact, this study 
has been designed in collaboration/consultation with 
a rounded group of stakeholders including patient and 
public representatives (eg, the Withington Heart Help 
Group and the Ticker Club) and industry (we have 
consulted with numerous manufacturers to confirm that 
work in this area is currently a high priority). Manchester 
University NHS Foundation Trust sponsors the study. Our 
consent procedure has been informed by prior experience 
within our national network of ambulance services, initial 
feedback from patient and public representatives (who 
have agreed with concern that judgement may be clouded 
in this acute situation) and the experience of AS in the 
Wellcome-funded ‘Network Exploring Ethics in Ambu-
lance Trials (NEAT)’ project.13
dISSEMInAtIon
Following completion of our analysis, we will discuss 
the significance of our findings and the key messages 
to be communicated at meetings of the Trial Steering 
Committee, Trial Management Group and Patient Advi-
sory Group. Following this, we will finalise our dissemina-
tion strategy. We will aim to publish our findings (positive 
or negative) in a high impact general medical journal with 
a relevant target audience (eg, British Medical Journal; 
The Lancet). In addition, we aim to present our findings 
to relevant target audiences at national and international 
conferences (eg, Royal College of Emergency Medicine 
Annual Scientific Conference; European Society of Cardi-
ology Annual Conference).
If our findings are positive, we will also develop an 
implementation strategy. This will involve working with 
commissioning groups (including NHS England and 
the Greater Manchester Joint Commissioning Board), 
NICE and Ambulance NHS Trusts to make the case for 
the clinical and cost effectiveness of our technology. 
Template clinical guidelines and training guides will be 
disseminated to ambulance services, and we anticipate 
proceeding to support pilot evaluations with a view to 
larger scale clinical implementation within 2 years.
Finally, we will work with stakeholder organisations 
including the National Ambulance Research Steering 
Group (NARSG; AS is a member) and the International 
Federation of Clinical Chemistry Committee for Cardiac 
Biomarkers (RB is a member) to enhance communica-
tion of our findings within the field.
dISCuSSIon
Based on our experience with previous studies, if our 
findings are positive we will aim to achieve clinical 
implementation within 2 years. Clearly, this will involve 
additional work to demonstrate the feasibility and accept-
ability of ‘live application’ of T-MACS in the ambulance; 
to develop new clinical guidelines and training regimes 
and to robustly communicate the clinical and cost effec-
tiveness of the strategy.
The recent update to NICE Guideline CG95 incorpo-
rated a novel diagnostic strategy (originally developed by 
our group) for in-hospital use based on data from obser-
vational studies with a similar design. Given that prece-
dent, we anticipate that our findings will generate the 
evidence required by NICE to issue a recommendation 
for the clinical use of T-MACS with a POC troponin assay 
in the prehospital environment.
We also implemented T-MACS in the hospital environ-
ment primarily based on observational data. The algo-
rithm has been applied in 8000 patients and has led to 
2/3 patients being safely treated in an ambulatory care 
environment without requiring hospital admission. 
Health Innovation Manchester, with access to a Joint 
Commissioning Board, has adopted T-MACS as an exem-
plar project for rapid implementation across Greater 
Manchester. We will conduct a ‘phase 4 evaluation’ of 
that regional implementation, aiming to achieve more 
widespread clinical implementation within 24 months 
of completion. If the findings of the proposed study are 
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positive, we will use a similar methodology to achieve 
rapid implementation in the prehospital environment.
If successfully implemented in practice, we anticipate 
that our findings will avoid the need for unnecessary 
ambulance transfers and hospital admission in approxi-
mately 40% of patients. As chest pain is the second most 
common reason for emergency ambulance calls and 
most common reason for emergency hospital admis-
sion, this is likely to have a substantial economic impact 
while reducing hospital overcrowding and its associated 
complications.
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